Top Medical Searches

Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome

(Reuters) – GlaxoSmithKline’s gene therapy for the so-called “bubble boy” disease was approved by Britain’s healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000).

 Read more…

Be Sociable, Share!
October 23rd, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us